Investors & Media

Investor Relations



NASDAQ: TGTX
Price
15.74
Change
- 0.26
Day High
16.31
Day Low
15.72
Volume
475,400
4:00 PM ET on May 29, 2015
Stock price graph
     

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop IRAK4 inhibitors, also for B-cell malignancies and autoimmune diseases. TG Therapeutics is headquartered in New York City.

Currently, TG Therapeutics uses the following social media channels:
- Twitter
- Facebook

View all »   RSSRecent Releases

May 29, 2015
TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the 51st Annual Meeting of the American Society of Clinical Oncology

May 13, 2015
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 51st Annual Meeting of the American Society of Clinical Oncology

View all »Events & Presentations

May 31, 2015 at 6:15 PM CT
TG THERAPEUTICS' 2015 ANALYST & INVESTOR EVENT